REGN250117P485000
- 0.00
- 0.000.00%
Regeneron Pharmaceuticals Newsroom
Regeneron Pharma Is Maintained at Overweight by Piper Sandler
Today's Analyst Rating | NVIDIA Price Target Raised to $200 by Cantor Fitzgerald, Alphabet-C Price Target Raised to $225 by Needham
Jan 27, Wall Street analysts have updated their stock ratings today including $NVIDIA(NVDA.US)$ and $Alphabet-C(GOOG.US)$.
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,013
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Is Regeneron Pharmaceuticals, Inc. (REGN) the Best Falling Stock to Invest in Right Now?
Express News | America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
America's Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,059
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,059 From $1,184, Maintains Outperform Rating
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Cuts Target Price to $1,185
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): 'This Company Has Never Lost Its Ability To Develop New Medicines'
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today
Express News | Regeneron Pharmaceuticals Inc : UBS Cuts to Neutral From Buy
UBS Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating, Cuts Target Price to $738
New opportunities for dividends: searching for future dividend stars.
The performance of dividend Stocks has been less than satisfactory in recent years, but now is the best time for investors to seek new opportunities.
Regeneron Pharmaceuticals Inc. Stock Rises Wednesday, Still Underperforms Market
The IL-33 monoclonal antibody developed by Sanofi (SNY.US) and Regeneron (REGN.US) has been clinically approved again in China for the treatment of chronic sinusitis.
The class 1 new drug itepekimab injection, submitted by Sanofi (SNY.US), has been approved for clinical use and is intended for the treatment of patients with chronic rhinosinusitis without nasal polyps (CRSsNP).
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,186
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Jim Cramer Says He Supports Healthcare Stocks for Their Long-term Value